Delray Beach, FLs, Aug. 19, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global molecular diagnostics market will grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6% during the forecast period. Market growth is fueled by the increasing prevalence of infectious diseases, cancer, and genetic disorders, rising government and private-sector investment in research and development, growing emphasis on personalized medicine, and technological advances in PCR, next-generation sequencing (NGS), and isothermal amplification.
Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833
Key Market Highlights
- Market size, 2024: USD 18.29 billion
- Market size, 2025: USD 19.48 billion
- Market forecast, 2030: USD 30.74 billion
- Growth rate: CAGR of 9.6% (2025–2030)
- Largest regional market: North America
- Largest product & service segment: Reagents & kits
- Largest end-user segment: Diagnostic laboratories
- Fastest regional growth opportunity: Asia Pacific
- Key players: Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), Hologic, Inc. (US)
Why This Market Matters
Molecular diagnostics is becoming increasingly important as healthcare systems seek faster, more accurate, and more targeted approaches to disease detection and monitoring. The rising prevalence of infectious diseases, cancer, and genetic disorders is increasing demand for molecular testing, while growing awareness of early disease detection and preventive healthcare is supporting broader adoption. Advances in PCR, NGS, and isothermal amplification are improving test speed, sensitivity, and versatility, while portable and rapid-turnaround platforms are helping smaller healthcare facilities incorporate molecular testing into routine workflows.
Market Overview
The molecular diagnostics market is witnessing sustained growth as hospitals, diagnostic laboratories, and clinics expand their use of advanced molecular testing technologies. Government funding, targeted R&D programs, and public-private partnerships are supporting the development of next-generation diagnostic platforms, including digital PCR, multiplex assays, and sequencing-based solutions. At the same time, expanding healthcare infrastructure and rising healthcare expenditure in emerging economies are creating new opportunities for molecular diagnostic manufacturers and service providers.
Analyst Perspective
The molecular diagnostics industry is moving toward faster, more accessible, and increasingly comprehensive testing workflows. The continued development of high-throughput platforms, automation-compatible reagents, multiplex assays, and sequencing technologies is helping laboratories improve efficiency and diagnostic accuracy. Companies that combine strong innovation pipelines with regulatory capabilities, strategic partnerships, product launches, and expansion into emerging markets are positioned to strengthen their competitive standing as demand for precise and timely molecular testing increases.
Speak to Our Analyst - Get Custom Insights:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=833
Segment Analysis
By product & service, reagents & kits accounted for the largest market share in 2024, supported by their broad applicability across PCR, NGS, and isothermal amplification workflows. High testing volumes, recurring consumption, and continued development of ready-to-use and automation-compatible formulations are supporting demand from hospitals, clinics, and diagnostic laboratories.
By end user, diagnostic laboratories accounted for the largest market in 2024. Increasing testing volumes for infectious diseases, cancer, and genetic disorders, combined with the need for advanced technical capabilities and high-throughput processing, is supporting the segment. Healthcare providers also increasingly outsource complex molecular testing to specialized laboratories because of their advanced instrumentation, trained personnel, and ability to adopt innovative assays efficiently.
Regional Analysis
North America accounted for the largest share of the molecular diagnostics market in 2024, supported by advanced healthcare infrastructure, robust laboratory networks, strong research capabilities, and the presence of leading molecular diagnostics companies. High adoption of innovative technologies, ongoing R&D investment, and supportive regulatory policies are further contributing to regional leadership. Asia Pacific is expected to register the highest CAGR during the forecast period, driven by increasing healthcare expenditure, rapid expansion of medical infrastructure, growing patient populations, and rising investments in diagnostic technologies.
Key Industry Trends
- Growing adoption of PCR, next-generation sequencing (NGS), and isothermal amplification technologies
- Increasing emphasis on personalized medicine and tailored treatment plans
- Rising demand for rapid, portable, and accurate molecular testing
- Growing use of multiplex testing to detect multiple targets in a single assay
- Increasing government initiatives and R&D funding for advanced molecular diagnostics
- Rising awareness of early disease detection and preventive healthcare
- Expansion of molecular diagnostic capabilities across emerging markets
Competitive Landscape
The competitive landscape of the molecular diagnostics market is led by established global companies including Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US), along with other prominent players such as QIAGEN N.V., Thermo Fisher Scientific Inc., Siemens Healthineers AG, Abbott, Revvity, Inc., Grifols S.A., QuidelOrtho Corporation, DiaSorin S.p.A., Becton, Dickinson and Company, Myriad Genetics, Inc., Agilent Technologies, Inc., Exact Sciences Corporation, MDxHealth, TBG Diagnostics Limited, Amoy Diagnostics Co., Ltd., Biocartis, Bruker, Genetic Signatures Ltd., Unijogen Oy, Vela Diagnostics, Molbio Diagnostics Limited, Savyon Diagnostics, and geneOmbio Technologies.
Danaher remains a leading player, supported by its strong US presence, international expansion strategy, product innovation, R&D investments, regulatory approvals, partnerships, and acquisitions. F. Hoffmann-La Roche Ltd. maintains a significant position through its broad geographic reach, extensive distribution network, and strategic acquisitions that strengthen its technology portfolio. Illumina is prominent in sequencing-based molecular diagnostics, with a strong NGS portfolio and applications spanning oncology, reproductive health, rare genetic disorders, and infectious disease testing.
The top five players in the molecular diagnostics market are Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., bioMérieux, and Hologic, Inc. Together, these companies contribute to market growth through technological innovation, regulatory clearances, global market expansion, and broad diagnostic portfolios.
Related Reports
In Vitro Diagnostics Market
Next-generation Sequencing Market
About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/
